37: 152/161Tb-DOTA-RM6 biodistribution studies in prostate cancer bearing SCID mice and 149Tb sources from CERN-MEDICIS von Buchegger, F, Baechler, S, Bühler, L, Deshayes, E, Gottberg, A, Kosinski, M, Maecke, H.R, Mansi, R, Müller, C, Prior, J.O, Schibli, R, Stora, T

Volltext

7037 POSTER Radiopeptide Therapy of Prostate Cancer LU-177-RM2 (BAY 1017858) Monotherapy and in Combination With PKI Inhibitors von Mansi, R, Dumont, R.A, Tamma, M.L, Deininger, F, Borkowski, S, Maecke, H.R, Weber, W.A

Volltext

Targeted therapy in nuclear medicine—current status and future prospects von Oyen, W. J. G., Bodei, L., Giammarile, F., Maecke, H. R., Tennvall, J., Luster, M., Brans, B.

Volltext

A comparison of In-111-DOTATOC and In-111-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours von Forrer, F., Uusijärvi, Helena, Waldherr, C., Cremonesi, M., Bernhardt, Peter, Mueller-Brand, J., Maecke, H.R.

Volltext

A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours von Forrer, F., Uusij rvi, H., Waldherr, C., Cremonesi, M., Bernhardt, P., Mueller-Brand, J., Maecke, H.R.

Volltext

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study von Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., Mueller-Brand, J.

Volltext

Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111 von Ruser, Gerd, Ritter, Walter, Maecke, Helmut R

Volltext

Exceptional Results in Neuroendocrine-Metastases-Caused Paraplegia Treated with [90Y-DOTA]-d -Phe1-Tyr3-octreotide (90Y-DOTATOC), a Radiolabelled Somatostatin Analogue von Waldherr, C., Haldemann, A., Maecke, H.R., Crazzolara, A., Mueller-Brand, J.

Volltext

Exceptional Results in Neuroendocrine-Metastases-Caused Paraplegia Treated with [ 90Y-DOTA]- d -Phe 1-Tyr 3-octreotide ( 90Y-DOTATOC), a Radiolabelled Somatostatin Analogue von Waldherr, C., Haldemann, A., Maecke, H.R., Crazzolara, A., Mueller-Brand, J.

Volltext

Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides von Breeman, Wouter A.P, Fröberg, A.C, de Blois, E, van Gameren, A, Melis, M, de Jong, M, Maina, T, Nock, B.A, Erion, J.L, Mäcke, H.R, Krenning, E.P

Volltext